What is antibody-drug conjugates treatment for urothelial cancer?

Question

Hello doctor,

I have been diagnosed with urothelial cancer, which has now spread to my upper urinary tract. My oncologist has informed me that surgery may no longer be effective and has mentioned antibody-drug conjugates (ADCs) as a newer treatment option. Could you please explain how ADCs work for urothelial cancer? Are they more effective than chemotherapy, or are they intended for specific stages of the disease? What side effects should I anticipate if I undergo this treatment? Additionally, are there any clinical trials available near me that I might be eligible to join?

Kindly help.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I read your query and understood your concern.

I am very sorry to hear about your diagnosis. Urothelial cancer involving both the bladder and upper urinary tract can be particularly challenging, especially in recurrent or advanced stages. Your oncologist's mention of antibody-drug conjugates is part of an important shift in cancer therapy, offering more targeted treatment options.

1. What are antibody-drug conjugates, and how do they work?

Antibody-drug conjugates are a new class of cancer treatments that combine the targeting ability of monoclonal antibodies with the cancer-killing effects of chemotherapy drugs. They work by binding to specific proteins (such as Nectin-4 or Trop-2) on cancer cells and internalizing into the cell and releasing a toxic payload directly inside the tumor. This approach allows for more precise tumor targeting with potentially less systemic toxicity than traditional chemotherapy.

The two most notable antibody-drug conjugates for urothelial cancer are:

Enfortumab Vedotin (Padcev) – targets Nectin-4.

Sacituzumab Govitecan (Trodelvy) – targets Trop-2.

2. Are antibody-drug conjugates better than chemotherapy?

It depends on your cancer stage, previous treatments, and overall health. Antibody-drug conjugates are currently used after prior chemotherapy or immunotherapy failure in locally advanced or metastatic urothelial carcinoma.

In some cases, they have shown higher response rates and better tolerability than second-line chemotherapy. Ongoing trials are exploring antibody-drug conjugates as first-line options or in combination with immunotherapy. They are not necessarily a “replacement” for chemotherapy, but they may offer better outcomes in certain patients and fewer side effects in some cases.

3. What side effects can you expect?

While often better tolerated than traditional chemotherapy, antibody-drug conjugates still have side effects, which may include fatigue, peripheral neuropathy, rash, and hair loss (common with Enfortumab Vedotin). Neutropenia, diarrhea, nausea, and liver enzyme elevation (more with Sacituzumab Govitecan). Infusion reactions or skin toxicities may also occur. Most side effects can be managed with supportive care or dose adjustments.

4. Are there clinical trials available?

Yes, ongoing clinical trials are investigating newer uses of antibody-drug conjugates, either alone or in combination with immune checkpoint inhibitors or targeted therapies. Ask your oncologist about local academic centers or National Cancer Institute-designated centers. You may be eligible for expanded access programs or compassionate use depending on your case.

Antibody-drug conjugates like Enfortumab Vedotin offer promising options for advanced urothelial cancer, especially when standard treatments are no longer effective. They are not universally better than chemotherapy but may be more targeted and tolerable in select cases. Careful evaluation by your oncology team, possibly with a clinical trial referral, will help guide the best treatment path forward.

I hope this helps.

Please let us know if you have any further queries. We would be happy to answer.

Thank you.